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The Big Short (1) tells the story of a small group of skeptics 
who profited from the financial crisis in 2007 by betting 
against collateralized (mortgage) debt obligations (CDO). 
Importantly, the novel paints a clear picture of the eccentric 
nature of contrarians who think divergently and against 
the grain or bet against an accepted truth or “sure” thing. 
In a similar manner, Ishii and co-workers’ recent work (2) 
describes their team’s development of a pulmonary imaging 
technology that provides divergent and disruptive in vivo 
lung measurements of oxygen partial pressure in the context 
of the prevailing and longstanding consensus around FEV1 
as the definitive diagnostic of chronic lung disease. 
It is well-understood and universally-accepted that the 
efficiency of pulmonary gas exchange is highly dependent 
on the symbiotic relationship between ventilation (oxygen 
delivery via the airways) and perfusion (oxygen uptake by 
the blood) that occur in the functional units of the lung, the 
alveoli. Accordingly, heterogeneity or mismatch between 
pulmonary ventilation and perfusion is a hallmark finding in 
respiratory diseases, such as chronic obstructive pulmonary 
disease (COPD). Indirect measurements of the alveolar 
partial pressure of oxygen (PAO2), such as arterial blood 
oxygen concentrations ([O2]) (3) and the measurement 
of the partial pressure of expired carbon dioxide-oxygen 
mixtures using helium washout (4), provide clinically-
acceptable measurements of gas exchange. Unfortunately, 
while these approaches provide physiologically relevant 
measures to support patient phenotyping and perhaps 
treatment decisions, these cannot provide regional 
information about ventilation, perfusion or its mismatch. 
This is important because in the last decade, lung imaging 
research has demonstrated that in obstructive lung diseases 
like asthma and COPD, lung functional abnormalities 
are regionally persistent and not randomly distributed 
throughout the lung. Accordingly, imaging methods, such as 
single photon emission computed tomography (SPECT) (5) 
and positron emission tomography (PET) (6), have been 
exploited to provide regional estimates of regional gas 
exchange and local partial pressures of oxygen. While also 
very useful, these imaging methods have limited spatial 
resolution and in addition, there is a small but clinically-
relevant risk to patients that stems from the ionizing 
radiation of the SPECT and PET contrast agents. An 
alternative imaging approach that does not pose such risks 
may also provide some helpful information and utilizes 
inhaled hyperpolarized noble gases and magnetic resonance 
imaging (MRI) (7).
Since its first description (8,9), hyperpolarized noble 
gas MRI, using either 3He or 129Xe gas, both of which are 
stable, non-ionizing isotopes that can be magnetized so they 
are MRI visible, has provided non-invasive measurements 
of lung ventilation and parenchymal morphology. Inhaled 
gas MRI has provided new insights into pulmonary 
physiology and biomechanics of COPD (10), asthma (11), 
cystic fibrosis (12), radiation-induced lung injury (13) and 
lung transplantation (14). This previous research has led to 
the development of oxygen-sensitive or oxygen-weighted 
noble gas MRI, first described by Saam and colleagues (15) 
in 1995. This pioneering study suggested the potential 
for MRI to spatial and temporal ventilation-perfusion 
and oxygen distribution/uptake in the lung via alveolar 
oxygen partial pressure maps (7,16). This method 
exploits a unique property of the hyperpolarized noble 
gas polarization decay rate that is directly related to the 
presence of molecular oxygen and linearly related with 
the local oxygen concentration. The oxygen-induced 
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relaxation measurements can then be used to estimate 
the regional PAO2 by measuring local differences in gas 
signal intensity (7). Although the method allows for rapid 
image acquisition to measure ventilation-perfusion match 
and oxygen uptake, a number of limitations including coil 
inhomogeneity, lung motion, delayed ventilation and/or 
diffusion have all significantly slowed clinical uptake and 
translation (17). Importantly, measurement variability has 
never yet been reported and this is absolutely required 
before such measurements can be used in clinical trials and 
for individual patient investigations. 
In an extension of these previous studies, Ishii and 
colleagues (2) endeavored to evaluate the test-retest 
reproducibility of alveolar oxygen tension measurements 
using 3He MRI in 25 subjects including 10 non-smokers and 
15 asymptomatic smokers. Reproducibility was measured 
using intra-class correlation coefficients and a mixed-effect 
model of PAO2. They showed there was no spatial or 
temporal difference in reproducibility in the non-smokers 
and the case-matched current smokers. Importantly, they also 
observed that although the cross-cohort repeatability was 
not significantly different, the spatial and temporal variability 
of PAO2 in smokers was greater than in non-smokers. 
Furthermore, a loss of gravity-dependent gradients in PAO2 
was observed in asymptomatic smokers-similar to previous 
work in mild-to-moderate COPD using 13N PET (18). In 
healthy, normal never-smokers, it is well-established that 
the lung deforms due to gravity and Ishii et al. showed 
clearly that such effects are regionally quantifiable using 
PAO2 mapping. Because the PAO2 maps clearly showed 
abnormalities in otherwise normal smokers, this suggests 
that such maps can be interrogated to detect early lung 
structure-function changes in asymptomatic smokers and 
ex-smokers.
This work showed for the f irst  t ime that PAO2 
measurements and maps provide the necessary and sufficient 
test-retest repeatability in non-smokers and asymptomatic 
smokers for novel biomarkers of COPD. Given this new 
information, it is now clear that PAO2 map and measurement 
variability beyond these thresholds may be ascribed, at least 
at this centre, to physiological changes that have occurred 
(alterations in gas exchange) as opposed to measurement 
error due to patient and technological factors. These 
reliability results should accelerate the more wide-spread use 
of MRI to develop novel lung disease imaging biomarkers 
based on PAO2. 
What is needed next to translate this method beyond 
imaging centres to respiratory care? Similar to other novel 
pulmonary imaging methods, patient motion/movement 
during image acquisition represents a predominant source 
of error that compounds subsequent image analyses 
especially when comparing images at multiple time-points. 
Image processing, including image registration provides 
a way to compensate for motion, although this may lead 
to other sources of error. The complex imaging protocol, 
pulse sequence, multinuclear hardware, and corrections 
needed to generate estimates of PAO2 may also slow or 
impede clinical translation. The system used to deliver 
the mixture of hyperpolarized 3He and oxygen requires 
simultaneous administration in a controlled fashion to 
eliminate depolarization of the gas prior to inhalation. This 
may reduce uptake in pediatric studies. Reproducibility of 
these measurements is also strongly dependent on image 
quality measured using the signal-to-noise ratio (SNR) 
which is dependent on many factors including polarization 
levels, the gas dispensing/delivery system for the patient 
and inhomogeneous signal acquisition via the thoracic coils 
used to capture the MRI signal. Finally and perhaps most 
importantly, there has been little opportunity to validate 
the regional PAO2 measurements generated using MRI. 
Once validated, widespread translation in clinical research 
and clinical care trials may help uncover the structural 
foundations of ventilation/perfusion mismatch. 
It is important to note that two decades after its first 
demonstration, hyperpolarized inhaled gas MRI is still 
limited to a handful of research centers worldwide. Some of 
the delay in clinical translation and uptake likely stems from 
the depleted global supply of 3He gas that has also resulted 
in significantly increased cost. What is clear is that moving 
forward, hyperpolarized 129Xe will be the translational target 
because the gas is naturally abundant and relatively less 
expensive with complexity and speed of image acquisition 
similar to 3He MRI. It is also clear that some of the physical 
properties of 129Xe gas including the gyromagnetic ratio and 
enrichment result in lower polarization and signal intensity 
making it more challenging (19) to acquire and measure 
complex quantitative phenotypes. The solubility of 129Xe 
in both blood and tissue adds another degree of freedom 
in the model used to estimate PAO2. Not to be confused 
with the current reproducibility demonstration of inhaled 
hyperpolarized 3He MRI, oxygen-enhanced measurements 
that stem from more conventional 1H MRI and inhaled O2 
also provides estimates of the partial pressure of oxygen 
dissolved in lung tissues (20). This is achieved by comparing 
T1-weighted 
1H images acquired whilst breathing room air 
(~21% [O2]) and pure oxygen (100% [O2]). This method 
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could potentially be used to validate or provide additional 
information that is complementary to oxygen-weighted 
hyperpolarized inhaled noble gas MRI. For all of these 
approaches however, what is yet required are streamlined 
and clinically-acceptable pipelines for both image 
acquisition and data analysis. Once integrated and accepted 
into clinical workflows, more widespread translation and 
use in clinical trials may be undertaken. 
Like the small group of contrarians who predicted the 
credit collapse and betted against the “mortgage” market (1), 
Ishii and co-workers (2) understand the risks inherent 
in the assumption that FEV1 will remain the dominant 
diagnostic for obstructive lung disease. They have bet 
on a different approach and invested in the development 
of oxygen-weighted noble gas MRI to generate PAO2 
measurements. While this is yet to be translated more 
widely, the biomarkers provided by MRI have the potential 
to generate new insights into mechanisms of pulmonary 
disease pathogenesis as well as the development and delivery 
of novel treatments. All of this is now urgently required if 
we are to stem the tidal wave of asthma and COPD costs—
both human and financial burdens that are being driven by 
an evolving demographic, environmental and other factors 
in the developed and developing world. 
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